Integrated DNA Technologies acquires oligonucleotide synthesis company ValueGene
Longze Cui (left) and General Manager of IDT West Coast Operations, Dan Dernbach (right), at the closing of the acquisition.
Company welcomes new customers with promise to provide seamless support for genomics research.
Integrated DNA Technologies (IDT) has acquired ValueGene, Inc., an oligonucleotide synthesis services company based in San Diego, California.
ValueGene offers custom DNA and RNA oligonucleotide synthesis products, including PAGE and HPLC purification and modification services.
Dr Joseph A Walder, IDT founder and CEO, said: “We look forward to maximizing the synergies between our two companies and building on ValueGene’s long history of providing quality products and services to its customers.”
Dan Dernbach, general manager of IDT’s West Coast operations, added: “ValueGene is well known in San Diego and Los Angeles. We welcome the opportunity to serve ValueGene’s customers and provide them the benefit of our portfolio of reagents for genomics research to support their important discoveries.”
Longze Cui of ValueGene said: “We are pleased to join IDT and are confident our customers will experience a smooth transition. Our customers, and their satisfaction, are our top priorities.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.